AG
PRQR icon

Aperio Group’s ProQR Therapeutics PRQR Stock Holding History

Aperio Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,112
Closed -$116K – 2382
2020
Q1 		$116K Buy
+21,112
New +$162K ﹤0.01% 2197
2019
Q3 		– Sell
-507
Closed -$5K – 2647
2019
Q2 		$5K Buy
+507
New +$5.98K ﹤0.01% 2861

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aperio Group's PRQR Position: Q2 2020 in Review

Aperio Group sold out of ProQR Therapeutics (PRQR) in Q2 2020, closing a stake of 21,112 shares — an estimated $116K sold.

Aperio Group first reported a position in PRQR in Q2 2019 and held it in 2 quarters. The position peaked at $116K in Q1 2020. 44 funds tracked by Wall St. Rank hold PRQR as of Q2 2020.

  • Aperio Group reported no remaining ProQR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Aperio Group sold 21,112 ProQR Therapeutics shares in Q2 2020, an estimated $116K.
  • Aperio Group first reported a position in ProQR Therapeutics in Q2 2019 and held it in 2 quarters.
  • Aperio Group's ProQR Therapeutics position peaked at $116K in Q1 2020.
  • 44 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2020.

Based on Aperio Group's 13F filing for Q2 2020, filed 13 Aug 2020.